Bio-Techne Corp TECH
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TECH is a good fit for your portfolio.
News
-
BIO-TECHNE TO PRESENT AT THE BofA SECURITIES HEALTH CARE CONFERENCE 2024
-
BIO-TECHNE TO PRESENT AT THE 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT)
-
BIO-TECHNE DECLARES DIVIDEND
-
BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2024 RESULTS
-
BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS
-
BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH THERMO FISHER SCIENTIFIC
-
BIO-TECHNE AND NOVOMOL-Dx ANNOUNCE POINT-OF-CARE OCULAR BIOMARKER ASSAY
-
BIO-TECHNE FILES PATENT INFRINGEMENT LAWSUIT AGAINST MOLECULAR INSTRUMENTS
Trading Information
- Previous Close Price
- $83.50
- Day Range
- $82.32–83.82
- 52-Week Range
- $51.79–89.91
- Bid/Ask
- $65.00 / $88.32
- Market Cap
- $13.05 Bil
- Volume/Avg
- 1.4 Mil / 1.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- 45.02
- Price/Sales
- 11.56
- Dividend Yield (Trailing)
- 0.39%
- Dividend Yield (Forward)
- 0.39%
- Total Yield
- 1.00%
Company Profile
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 3,050
- Website
- https://www.bio-techne.com
Comparables
Valuation
|
Metric
|
TECH
|
TIHE
|
BIO
|
|---|---|---|---|
Price/Earnings (Normalized) | 45.02 | — | 24.69 |
Price/Book Value | 6.48 | — | 0.93 |
Price/Sales | 11.56 | — | 3.29 |
Price/Cash Flow | 42.03 | — | 12.49 |
Price/Earnings
TECH
TIHE
BIO
Financial Strength
|
Metric
|
TECH
|
TIHE
|
BIO
|
|---|---|---|---|
Quick Ratio | 2.49 | — | 4.48 |
Current Ratio | 4.08 | — | 6.57 |
Interest Coverage | 14.52 | — | −9.70 |
Quick Ratio
TECH
TIHE
BIO
Profitability
|
Metric
|
TECH
|
TIHE
|
BIO
|
|---|---|---|---|
Return on Assets (Normalized) | 10.95% | — | 2.73% |
Return on Equity (Normalized) | 14.98% | — | 3.84% |
Return on Invested Capital (Normalized) | 12.39% | — | 2.95% |
Return on Assets
TECH
TIHE
BIO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zrddgjnzs | Tfql | $586.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fhxsmmm | Mqpqng | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Txtmbspld | Psxfnpb | $106.7 Bil | |
MRNA
| Moderna Inc | Jgjbvhftl | Gqp | $50.8 Bil | |
BNTX
| BioNTech SE ADR | Qfnhgzz | Bwzq | $22.4 Bil | |
ARGX
| argenx SE ADR | Vgxlpdz | Hddly | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Glzvrvdh | Gnbqyx | $19.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bkmqktrr | Cvswpyy | $14.6 Bil | |
INCY
| Incyte Corp | Jgbznbvb | Kscnw | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Chjzmdmm | Vnqvg | $12.6 Bil |